MedRhythms, a Portland-based company that combines sensors, neuroscience and music to help people recover from neurologic injury or disease, announced Friday it raised $5 million in an oversubscribed Series A Financing round. The company stated in a news release that it intended to raise $4 million but due to substantial interest it raised the offering to $5.3 million. By the time of Friday’s announcement, it had raised $5 million. This investment will allow MedRhythms to develop and launch a patent-pending digital therapeutics platform that focuses on building evidence-based, FDA-approved, prescription products for people with neurologic injuries and diseases to improve and measure walking. While the first product on the platform focuses on the post-stroke population, the pipeline includes products for Parkinson’s disease, multiple sclerosis, aging-In-place and traumatic brain injury. Read more here.
Related Posts
Maine’s life sciences sector growth could outpace other industries
Maine’s $2.3 billion life sciences sector, which employed close to 10,000 people in 2024, will outpace the growth of many other...
IDEXX gets wiggle room to buy back more shares
IDEXX Laboratories Inc. (Nasdaq: IDXX), a Westbrook-based maker of veterinary diagnostics and software, has the green light from its board of...
Maine’s first accredited lab for PFAS testing is expanding to meet demand
NORRIDGEWOCK, Maine — This week, the Biden administration moved to prevent dangerous “forever chemicals” from being released onto the market after a less...